Since late 2022, bad news in biotech has been nearly inescapable: flopped trials, slashed drug pipelines, bankruptcies and ...

Officials with Arvinas, a New Haven-based biotechnology firm, announced Thursday that the company is laying off 131 workers at the end of June, including 92 in Connecticut. The company announced ...

Lately in the Boston life sciences industry, a Newton biotech cut 20% of its workforce, Novartis signed a deal with a Waltham ...

Headed up by former Merck & Co. executive Roger Perlmutter, M.D., Ph.D., the biotech went on to secure a series of megarounds, with the most ambitious being a $517 million series B in 2022 and the ...

Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from ...

According to the latest figures from MassBio, Massachusetts' biotech industry association, the state’s workforce growth has slowed, only growing 2.5% in 2023, after two earlier years of 7.8% ...

The Philadelphia gene therapy company said the cuts were "part of a broader effort to right size the organization." ...

Massachusetts’ biotech workforce remained relatively stagnant last year, following several years of slowing growth, according to data released Tuesday by MassBioEd, an industry group focused on ...

The R&D tax credit isn’t the only area in which changes to tax policy could boost the biotech industry in Connecticut. Currently, the state’s R&D tax credit is available only to C Corporations.